A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan
Authors:
Open Access
- 11 September 2023
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (2) , 475-488
Abstract
Real-world studies permit inclusion of a more diverse patient population and provide more information on the effectiveness of treatments used in routine clinical practice. This prospective, multicenter, observational study investigated the effectiveness and safety of ixazomib plus lenalidomide and dexamethasone (IRd) in 295 patients with relapsed/refractory multiple myeloma (RRMM) in routine clinical practice in Japan. Patients had a median age of 74 years, 80.0% were aged ≥ 65 years, 42.0% had received ≥ 3 lines of prior treatment, and 28.5% were “frail” according to the International Myeloma Working Group frailty score. After a median follow-up of 25.0 months, median progression-free survival (PFS) was 15.3 (95% CI 12.4–19.5) months, while median overall survival was not reached. The overall response rate was 53.9%, and 31.5% of patients had a very good partial response or better. In the subgroup analysis, median PFS was better in patients with 1 versus 2 or ≥ 3 lines of prior treatment (29.0 vs 19.2 or 6.9 months) and paraprotein versus clinical relapse (16.0 vs 7.9 months), but median PFS was not notably affected by frailty score or age group. Dose adjustment was more frequent among patients aged > 75 years, especially early after IRd treatment initiation. Treatment-emergent adverse events (TEAEs) of any grade occurred in 84.4% of patients and 24.7% of patients discontinued treatment due to TEAEs; no new safety concerns were found. These findings suggest that oral IRd triplet regimen is an effective and tolerable treatment option for RRMM patients in real-world settings outside of clinical trials.ClinicalTrials.gov identifier: NCT03433001; Date of registration: 14 February 2018.Keywords
Funding Information
- Takeda Pharmaceutical Co. Ltd.
This publication has 33 references indexed in Scilit:
- Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patientsBlood, 2017
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literaturePatient Preference and Adherence, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Cytogenetic abnormality in patients with multiple myeloma analyzed by fluorescent in situ hybridizationOncoTargets and Therapy, 2016
- Spotlight on ixazomib: potential in the treatment of multiple myelomaDrug Design, Development and Therapy, 2016
- Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2015
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2015
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human CancerCancer Research, 2010